Abstract: A moving mechanism includes a support; a driving device mounted on the support; a controller arranged on the support; two sets of moving assemblies respectively mounted at two ends of the support; wherein each of the moving assemblies includes a track and two synchronous wheels of different diameters arranged inside the track, such that the moving mechanism is functioned and run freely over stairs, rugged road surfaces and all-terrain ground under the action of the driving device and the controller. Besides, the moving mechanism is equipped on electric vehicles and toys. The moving mechanism applies a breakthrough composite structure of a half-wheel-half-track configuration in combination with an additional omni-directional wheel, whereby the moving mechanism and the electric vehicles and toys equipping the same are adaptable to different road surfaces and stairs of various angles, and also convenient and reliable to use.

Abstract: The present invention discloses a moving mechanism including a support; a driving device mounted on the support; a controller arranged on the support; two sets of moving assemblies respectively mounted at two ends of the support; wherein each of the moving assemblies includes a track and two synchronous wheels of different diameters arranged inside the track, such that the moving mechanism could be functioned and run freely over stairs, rugged road surface and all-terrain ground under the action of the driving device and the controller. The present invention also discloses electric vehicles and toys equipping the moving mechanism.

Abstract: Disclosed herein are compositions and methods for decreasing vascular permeability in a blood vessel and treating or preventing conditions associated with defects or injuries of vascular endothelium. For example, the disclosed compositions and methods can be used to treat a vascular dysplasia such as cerebral cavernous malformation (CCM). These methods relate generally to the use of compositions that inhibit RhoA GTPase levels or activity, such as inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.